{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:51:28Z","timestamp":1791564688547,"version":"4.3.4"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shizuoka Prefecture"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Sleep drugs are often necessary to treat insomnia in older patients. Benzodiazepine receptor agonists (BZRAs) are primarily used for insomnia in these patients, but there are concerns regarding their association with delirium and bone fractures. Among sleep drugs, orexin receptor antagonists such as suvorexant have a lower risk of delirium than BZRAs, but their effectiveness in preventing hip fractures is unknown. Hip fracture is a life-threatening trauma in advanced-age patients and a social problem. Therefore, we investigated the relationship between suvorexant and hip fracture. The Shizuoka Kokuho Database was used to compare the time to hip fracture in patients who had been newly taking suvorexant and other sleep drugs such as benzodiazepines since November 2014. A proportional hazards model for hip fracture as an outcome was used to estimate the hazard ratio. Propensity scores were estimated using a logistic regression model, and the confounding factors were age, sex, several comorbidities, and each oral medication. The suvorexant group comprised 6860 patients (110 with hip fracture), and the BZRA group (benzodiazepines and Z-drugs) comprised 50,203 patients (1487 with hip fracture). In the matched cohort (6855:6855 patients), 259 and 249 patients in the suvorexant and BZRA group developed hip fractures during the observational period, respectively. The hazard ratio of the suvorexant group compared with the BZRA group was 1.48 (95% confidence interval, 1.20\u20131.82). In the subgroup analysis, patients in the suvorexant group had a higher risk of hip fracture if they were aged &gt;75 years, had no diabetes, had no neurological disease, had no renal failure, had liver disease, had hypertension, were not taking alpha 1 blockers, and were not taking oral steroids. Among people in the Japanese regional population who use sleep drugs, patients taking suvorexant can be at higher risk of hip fracture than patients taking BZRAs.<\/jats:p>","DOI":"10.1371\/journal.pone.0284726","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T17:30:27Z","timestamp":1682357427000},"page":"e0284726","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effectiveness of suvorexant versus benzodiazepine receptor agonist sleep drugs in reducing the risk of hip fracture: Findings from a regional population-based cohort study"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-2977","authenticated-orcid":true,"given":"Ryozo","family":"Yoshioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-446X","authenticated-orcid":true,"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"pone.0284726.ref001","first-page":"41","article-title":"An epidemiological study of insomnia among the Japanese general population.","volume":"23","author":"K Kim","year":"2000","journal-title":"Sleep"},{"key":"pone.0284726.ref002","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/smrv.2002.0186","article-title":"Epidemiology of insomnia: what we know and what we still need to learn","volume":"6","author":"MM Ohayon","year":"2002","journal-title":"Sleep Med Rev"},{"key":"pone.0284726.ref003","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00198-009-0920-3","article-title":"Excess mortality following hip fracture: a systematic epidemiological review.","volume":"20","author":"B Abrahamsen","year":"2009","journal-title":"Osteoporos Int"},{"key":"pone.0284726.ref004","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1046\/j.1532-5415.2002.50455.x","article-title":"Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study.","volume":"50","author":"CL Leibson","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"pone.0284726.ref005","doi-asserted-by":"crossref","first-page":"715.e7","DOI":"10.1016\/j.jamda.2015.05.013","article-title":"Risk of nursing home admission after femoral fracture compared with stroke, myocardial infarction, and pneumonia.","volume":"16","author":"K Rapp","year":"2015","journal-title":"J Am Med Dir Assoc."},{"key":"pone.0284726.ref006","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12877-015-0154-5","article-title":"Risk of hip fracture among older people using antihypertensive drugs: a nationwide cohort study.","volume":"15","author":"S Ruths","year":"2015","journal-title":"BMC Geriatr."},{"key":"pone.0284726.ref007","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00198-012-2053-3","article-title":"Diuretic initiation and the acute risk of hip fracture.","volume":"24","author":"SD Berry","year":"2013","journal-title":"Osteoporos Int"},{"key":"pone.0284726.ref008","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"TP Van Staa","year":"2000","journal-title":"J Bone Miner Res"},{"key":"pone.0284726.ref009","doi-asserted-by":"crossref","first-page":"h5398","DOI":"10.1136\/bmj.h5398","article-title":"The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist: a population based cohort study","volume":"351","author":"B Welk","year":"2015","journal-title":"BMJ"},{"key":"pone.0284726.ref010","doi-asserted-by":"crossref","first-page":"e1915348","DOI":"10.1001\/jamanetworkopen.2019.15348","article-title":"Association of receiving multiple, concurrent fracture-associated drugs with hip fracture risk","volume":"2","author":"RT Emeny","year":"2019","journal-title":"JAMA Netw Open"},{"key":"pone.0284726.ref011","doi-asserted-by":"crossref","first-page":"j2941","DOI":"10.1136\/bmj.j2941","article-title":"Benzodiazepines and risk of all cause mortality in adults: cohort study","volume":"358","author":"E Patorno","year":"2017","journal-title":"BMJ"},{"key":"pone.0284726.ref012","doi-asserted-by":"crossref","first-page":"e0174730","DOI":"10.1371\/journal.pone.0174730","article-title":"Benzodiazepines, Z-drugs and the risk of hip fracture: a systematic review and meta-analysis.","volume":"12","author":"K Donnelly","year":"2017","journal-title":"PLoS One."},{"key":"pone.0284726.ref013","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3961\/jpmph.2012.45.4.219","article-title":"Zolpidem use and risk of fracture in elderly insomnia patients.","volume":"45","author":"D-Y Kang","year":"2012","journal-title":"J Prev Med Public Health."},{"key":"pone.0284726.ref014","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jamainternmed.2013.3795","article-title":"Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents","volume":"173","author":"SD Berry","year":"2013","journal-title":"JAMA Intern Med"},{"key":"pone.0284726.ref015","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00198-016-3605-8","article-title":"Zolpidem use and risk of fractures: a systematic review and meta-analysis.","volume":"27","author":"SM Park","year":"2016","journal-title":"Osteoporos Int."},{"key":"pone.0284726.ref016","doi-asserted-by":"crossref","first-page":"e970","DOI":"10.4088\/JCP.16m11194","article-title":"Preventive effects of suvorexant on delirium: a randomized placebo-controlled trial.","volume":"78","author":"K Hatta","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"pone.0284726.ref017","doi-asserted-by":"crossref","first-page":"19m12865","DOI":"10.4088\/JCP.19m12865","article-title":"Real-world effectiveness of ramelteon and suvorexant for delirium prevention in 948 patients with delirium risk factors.","volume":"81","author":"K Hatta","year":"2019","journal-title":"J Clin Psychiatry."},{"issue":"Pt 3","key":"pone.0284726.ref018","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1113\/jphysiol.2002.033290","article-title":"Orexins induce increased excitability and synchronisation of rat sympathetic preganglionic neurones","volume":"549","author":"M van den Top","year":"2003","journal-title":"J Physiol"},{"key":"pone.0284726.ref019","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1074\/jbc.M406073200","article-title":"Orexin-A-induced Ca2+ entry: evidence for involvement of trpc channels and protein kinase C regulation","volume":"280","author":"KP Larsson","year":"2005","journal-title":"J Biol Chem"},{"key":"pone.0284726.ref020","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12264-019-00447-9","article-title":"Orexin receptor antagonists as emerging treatments for psychiatric disorders","volume":"36","author":"Y Han","year":"2020","journal-title":"Neurosci Bull"},{"key":"pone.0284726.ref021","doi-asserted-by":"crossref","first-page":"e21043","DOI":"10.1097\/MD.0000000000021043","article-title":"Suvorexant for the prevention of delirium: a meta-analysis.","volume":"99","author":"S Xu","year":"2020","journal-title":"Medicine (Baltimore)."},{"key":"pone.0284726.ref022","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2188\/jea.JE20200480","article-title":"Data resource profile of Shizuoka Kokuho Database (SKDB) Using integrated health- and care-insurance claims and health checkups: The Shizuoka Study.","volume":"32","author":"E Nakatani","year":"2022","journal-title":"J Epidemiol"},{"key":"pone.0284726.ref023","doi-asserted-by":"crossref","first-page":"n189","DOI":"10.1136\/bmj.n189","article-title":"Association between antihypertensive treatment and adverse events: systematic review and meta-analysis","volume":"372","author":"A Albasri","year":"2021","journal-title":"BMJ"},{"key":"pone.0284726.ref024","doi-asserted-by":"crossref","first-page":"e024067","DOI":"10.1136\/bmjopen-2018-024067","article-title":"Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis","volume":"9","author":"H Wang","year":"2019","journal-title":"BMJ Open"},{"key":"pone.0284726.ref025","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1186\/s12913-020-05690-9","article-title":"An analysis of equity in treatment of hip fractures for older patients with dementia in acute care hospitals: observational study using nationwide hospital claims data in Japan.","volume":"20","author":"S Tomioka","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"pone.0284726.ref026","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0022-510X(00)00458-5","article-title":"Risk factors for hip fracture among elderly patients with Parkinson\u2019s disease","volume":"182","author":"Y Sato","year":"2001","journal-title":"J Neurol Sci"},{"key":"pone.0284726.ref027","doi-asserted-by":"crossref","first-page":"b4229","DOI":"10.1136\/bmj.b4229","article-title":"Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores","volume":"339","author":"J Hippisley-Cox","year":"2009","journal-title":"BMJ"},{"key":"pone.0284726.ref028","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"H Quan","year":"2005","journal-title":"Med Care."},{"key":"pone.0284726.ref029","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2202\/1557-4679.1125","article-title":"Fitting smooth-in-time prognostic risk functions via logistic regression.","volume":"5","author":"JA Hanley","year":"2009","journal-title":"Int J Biostat"},{"key":"pone.0284726.ref030","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Web Site and R Package for Computing E-values.","volume":"29","author":"MB Mathur","year":"2018","journal-title":"Epidemiology"},{"key":"pone.0284726.ref031","article-title":"Comparative risk of fracture in community-dwelling older adults initiating suvorexant versus Z-drugs: results from LIFE study.","author":"M Adomi","year":"2022","journal-title":"J Am Geriatr Soc."},{"key":"pone.0284726.ref032","doi-asserted-by":"crossref","first-page":"1071962","DOI":"10.3389\/fpsyt.2023.1071962","article-title":"Physicians\u2019 attitudes toward hypnotics for insomnia: a questionnaire-based study.","volume":"14","author":"M Takeshima","year":"2023","journal-title":"Front Psychiatry"},{"key":"pone.0284726.ref033","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"WJ Herring","year":"2016","journal-title":"Biol Psychiatry"},{"key":"pone.0284726.ref034","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/NSS.S76910","article-title":"Novel class of medications, orexin receptor antagonists, in the treatment of insomnia\u2014critical appraisal of suvorexant.","volume":"8","author":"JL Norman","year":"2016","journal-title":"Nat Sci Sleep."},{"key":"pone.0284726.ref035","first-page":"491","article-title":"Suvorexant: a promising, novel treatment for insomnia.","volume":"12","author":"JK Lee-Iannotti","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"pone.0284726.ref036","doi-asserted-by":"crossref","first-page":"e13371","DOI":"10.2196\/13371","article-title":"Adverse events due to insomnia drugs reported in a regulatory database and online patient reviews: comparative study","volume":"21","author":"JS Borchert","year":"2019","journal-title":"J Med Internet Res"},{"key":"pone.0284726.ref037","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/psyg.12858","article-title":"Effectiveness of change from suvorexant to lemborexant drug in the treatment of sleep disorders.","volume":"22","author":"K Okino","year":"2022","journal-title":"Psychogeriatrics"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T10:23:25Z","timestamp":1702290205000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284726"}},"subtitle":[],"editor":[{"given":"Norio","family":"Yasui-Furukori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0284726","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]}}}